Should NICE's threshold range for cost per QALY be raised? Yes.
Towse
Adrian
A
Office of Health Economics, London SW1A 2DY. atowse@ohe.org
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005102:Health Expenditures; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics*; D011320:Primary Health Care / Q000191:economics; D019057:Quality-Adjusted Life Years; D013222:State Medicine / Q000191:economics*; D006113:United Kingdom
D004364:Pharmaceutical Preparations